Abstract
A key feature of the clinical course of chronic lymphocytic leukemia (CLL) is that it induces a state of immunosuppression, causing increased susceptibility to infections and failure of anti-tumor immune responses. Cytotoxic chemotherapy still forms the mainstay of most current treatment regimens, but is not curative, and its lack of specificity means that it also targets normal immune cells, exacerbating this immunosuppression. This can result in effective treatments being limited by infectious complications, particularly in the elderly who comprise the majority of patients with this disease. Immunotherapy potentially offers a way out of this dilemma, due to its improved specificity and ability to enhance immune responses to both the tumor and infectious agents. There has been a dramatic increase in the range of available immunotherapeutic options over the past decade, and many are now in the process of making the transition to the clinic. This review will discuss both the immune defect in CLL, and emerging immunotherapies, including CD40 ligand gene therapy, lenalidomide, CLL vaccines, CXCR4 antagonists, and adoptive cellular immunotherapies such as chimeric antigen receptor modified T-cells.
Keywords: Chronic lymphocytic leukemia, immune suppression, T-cell, NK-cell, CXCR4, plerixafor, CAL-101, everolimus, PCI-32765, CD40 ligand, gene therapy, lenalidomide, cancer vaccine, allogeneic hemopoietic stem cell transplantation, chimeric antigen receptor
Current Pharmaceutical Design
Title:Immune Dysfunction in Chronic Lymphocytic Leukemia: The Role for Immunotherapy
Volume: 18 Issue: 23
Author(s): John C. Riches, Alan G. Ramsay and John G. Gribben
Affiliation:
Keywords: Chronic lymphocytic leukemia, immune suppression, T-cell, NK-cell, CXCR4, plerixafor, CAL-101, everolimus, PCI-32765, CD40 ligand, gene therapy, lenalidomide, cancer vaccine, allogeneic hemopoietic stem cell transplantation, chimeric antigen receptor
Abstract: A key feature of the clinical course of chronic lymphocytic leukemia (CLL) is that it induces a state of immunosuppression, causing increased susceptibility to infections and failure of anti-tumor immune responses. Cytotoxic chemotherapy still forms the mainstay of most current treatment regimens, but is not curative, and its lack of specificity means that it also targets normal immune cells, exacerbating this immunosuppression. This can result in effective treatments being limited by infectious complications, particularly in the elderly who comprise the majority of patients with this disease. Immunotherapy potentially offers a way out of this dilemma, due to its improved specificity and ability to enhance immune responses to both the tumor and infectious agents. There has been a dramatic increase in the range of available immunotherapeutic options over the past decade, and many are now in the process of making the transition to the clinic. This review will discuss both the immune defect in CLL, and emerging immunotherapies, including CD40 ligand gene therapy, lenalidomide, CLL vaccines, CXCR4 antagonists, and adoptive cellular immunotherapies such as chimeric antigen receptor modified T-cells.
Export Options
About this article
Cite this article as:
C. Riches John, G. Ramsay Alan and G. Gribben John, Immune Dysfunction in Chronic Lymphocytic Leukemia: The Role for Immunotherapy, Current Pharmaceutical Design 2012; 18 (23) . https://dx.doi.org/10.2174/138161212801227023
DOI https://dx.doi.org/10.2174/138161212801227023 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Fibromyalgia
Current Rheumatology Reviews Biomarkers in Acute Heart Failure Syndromes: An Update
Current Cardiology Reviews Noradrenaline in Parkinsons Disease: From Disease Progression to Current Therapeutics
Current Medicinal Chemistry A Systematic Review of Randomized Controlled Trials Examining the Nephroprotective Properties of Antihypertensive Medications
Current Hypertension Reviews The Role of Vitamin D in Dyslipidemia and Cardiovascular Disease
Current Pharmaceutical Design Mechanisms of the Blunting of the Sympatho-Adrenal Response: A Theory
Current Diabetes Reviews A Proposal----The Renal Kallikrein-Kinin System as a Compensating System for Salt Accumulation after Excess Salt Intake
Current Hypertension Reviews Mechanisms Involved in Apoptosis Events Contributing to Sepsis-Induced Myocardial Dysfunction
Current Drug Therapy Recent Advances in Pulmonary Hypertension Therapy
Recent Patents on Cardiovascular Drug Discovery Neuroprotective Role of Agmatine in Neurological Diseases
Current Neuropharmacology Antisense Therapy for Cardiovascular Diseases
Current Pharmaceutical Design Corticotropin-Releasing Factor Receptor Antagonists in Affective Disorders and Drug Dependence - An Update
CNS & Neurological Disorders - Drug Targets Cardiovascular-Related
Current Bioactive Compounds Angiotensin Converting Enzyme Inhibitory Peptides Derived from Food Proteins: Biochemistry, Bioactivity and Production
Current Pharmaceutical Design Ligands of Diltiazem Binding Site: An Overview of Some Chemotypes
Mini-Reviews in Medicinal Chemistry A Review of the Cardiovascular and Anti-Atherogenic Effects of Ghrelin
Current Pharmaceutical Design Irbesartan and Hydrochlorothiazide Association in the Treatment of Hypertension
Current Vascular Pharmacology Emerging Antimicrobial Applications of Nitric Oxide (NO) and NO-Releasing Materials
Anti-Infective Agents in Medicinal Chemistry The Effect of Coconut Jelly with Stevia as a Natural Sweetener on Blood Glucose, Insulin and C-Peptide Responses in Twelve Healthy Subjects
Recent Patents on Food, Nutrition & Agriculture What is Currently the Best Radiopharmaceutical for the Hybrid PET/CT Detection of Recurrent Medullary Thyroid Carcinoma?
Current Radiopharmaceuticals